70 results
The most important objectives of this study:1) examine the bacterial translocation as a consequence of elevated intestinal permeability in the morbid obese compared to controls, and to proove this is causes an inflammatory status predisposing IR/…
Hypothetically, in patients with PBC or PSC the FGF-19 production or -response could be altered. The goal of this research is to study the FGF19 production after a standardized oral fat challenge and the effect of this FGF19 production on bile acid…
The aim of this study is to investigate the effect of ATP8B1 carrier on hearing in human.
To determine if LA is a familial disease. To identify germline mutations in HNF-1 alpha, ß-catenin and CYP1B1 genes in LA patients. To screen first degree relatives of patients diagnosed with liver adenomatosis for the presence of liver adenomas and…
The aim of this study is to determine whether nose potential difference response is impaired in patients with FIC1-deficiency.
We want to evaluate the relation between intestinal integrity and the constitution of the intestinal microbiota, versus inflammatory and insulin resistance in patients with morbid obesity and patients with a normal weight.
To investigate whether the expression of renal water and sodium transporters in urinary exosomes is different in compensated versus decompensated liver and heart disease.
Assessment of hepatic HSPG*s in NASH associated dyslipidemia in 8 subjects with DM2 associated NASH (insulin resistant, n=8) vs NASH in FHBL (non insulin resistant, n=8) and control subjects (hemochromatosis, n=8)
To demonstrate and compare expression of CCL25 and CCR9+ lymphocytes in peripheral blood and colon of PSC-, PSC/IBD-, IBD-, gastroenteritis patients and controls.
To set up a cohort of HIV infected MSM who subsequently acquired HCV infection with a known date of HCV seroconversion to study:- determinants/risk factors for acquiring HCV in HIV infected MSM- the outcome of HCV treatment in this population- the…
To determine the 1 year sustainability of the effects of a lifestyle intervention on NAFLD in severely obese children and determine the relation between long term changes in liver steatosis and other clinical and biochemical parameters. Finally, to…
Primary aimTo evaluate the effects of peginterferon and ribavirin therapy on the immune response in chronic HCV genotype 1 patients before, during and after treatment.Secondary aims1. To determine if differential modulation of Treg activity or DC…
A proof-of-principle study to test whether an environmental factor, i.e. here IFNα treatment, induces epigenetic alterations of certain genes in blood lymphocytes and whether these alterations correlate with the severity of psychiatric symptoms, i.e…
- Is there a correlation between liver fat content and inflammation in patients with or without STNFR-2 polymorphisms (-1031C, -863A)?- What is the correlation between weight reduction and decrease of hepatic steatosis?- What is the correlation…
The primary aim is to characterize mucosal immune responses in concomitant PSC and IBD. Secondary objectives are (1) to identify phenotype and function of the mucosal immune responses in peripheral blood, liver and intestinal biopsies of patients…
Primary objective: to investigate the incidence of IAC in patients resected for presumed PHC.Secundary objectives:- Evaluation of the diagnostic accuracy of histological criteria for IAC compared to IgG4 qPCR test- Evaluation of disease activity by…
Primary objective is to evaluate and compare the glycaemic control in T2DM within the first year of LRYGB and LMBG. Secondary aim is to gain insight in the pathophysiological mechanisms that drive the conversion of malign to benign obesity.
To gain insight in the metabolic, microbiota and immunologic changes after bariatric surgery that drive NAFLD/NASH and weightless resulting in subsequent conversion of malign to benign obesity.
We aim to identify hepatic, plasma, genetic and gutmicrobial markers that, alone or in combination, enable detection and monitoring of disease progression from NAFLD to NASH and subsequent progression from NASH to cirrhosis.
1. To identify a biomarker of hepatic DNL in different disease models of NAFLD. 2. To assess the cardiovascular risk profile in the different disease models of NAFLD.